Mayoly Gastro Days 2024: Your connection to the latest advancements and insights in hepato-gastroenterology!

Connect on December 13-14 as we team up with 11 leading European experts to discuss pivotal advances in hepato-gastroenterology.

Expect engaging discussions, valuable expert insights, and shared practices to elevate your expertise in gastroenterology.

Be informed of the full program and REGISTER for this special event here

Our CSR approach is supported by our purpose, “improving health and well-being for everyone to offer a better daily life for each individual,” and contributes to our ambition of becoming a global leader in public health.

Discover the 2023 report.

At Mayoly, we are dedicated to supporting patients. We are pleased to introduce the Logbook, a guide designed to help patients prepare effectively before a colonoscopy.

The importance of a good preparation

We launched this project in order to raise awareness among patients about the importance of preparation, and then about the bowel cleansing solution, before a colonoscopy. This document provides clear information, practical advice and tips to ensure that the examination goes as good as possible.

A guide by a patient for patients

This guide was developed in partnership with Pierre-Louis Attwell, a navigator and patient with Crohn’s disease. Having undergone multiple medical procedures, Pierre-Louis can authentically speak about the importance of the preparation before a colonoscopy. His personal experience perfectly illustrates why proper preparation is crucial for a successful procedure. It is important to remember that this exam is critical for detecting precancerous lesions. The quality of the examination largely depends on the preparation, including the bowel preparation.

Find Pierre-Louis’s interview here.

What you will find within the logbook

This document is designed to serve as a guide throughout the preparation process before a colonoscopy. Inside, you will find:

· A clear explanation of what bowel cleansing solution is and why it is so important,

· Practical recommendations for drinking bowel cleansing effectively,

· Advice on the low-residue diet recommended before the colonoscopy,

· Definitions of key terms related to the procedure and preparation,

· A checklist at the end of the guide to follow the essential steps.

Download it!

To view and download the Logbook, click here. This guide is available for free, and we encourage you to share it with anyone who might benefit from it.

Our Executive Committee is welcoming a new member: Gael Chalvon Demersay as Mergers & Acquisitions, Business Development and Alliances Director, effective on June 17, 2024.He succeeds Emmanuel Botzung who has left the group.

He graduated from HEC (Hautes Etudes Commerciales) Paris (Paris Business School) with a Master’s degree in Corporate Finance and Strategy and began his career in 2014 as a consultant at the Boston Consulting Group.

In 2019, he was appointed Director of Strategy and M&A at Laboratoires Juvisé Pharmaceuticals, where he was responsible for external growth alliances and business development.

Together, let’s continue to grow in a changing world and build our future! Discover our successes and 2023 highligts.

We aspire to become a benchmark in consumer healthcare and to become one of the world’s Top 20 Consumer Healthcare companies in our markets, by moving towards greater well-being and closeness to our stakeholders. This ambition is based on what unites us – our values, our strong French industrial base, our world-famous brands and the talent of our teams – but also on what makes us complementary – our business areas, our product portfolios and our international presence. This new ambition for the Group is accompanied by a new visual territory with a strong conviction, a new name to gather the various entities, with a new logo and a new signature.

L’ouverture de 7 nouvelles filiales marque une étape essentielle dans la finalisation de l’intégration d’IPSEN CHC au sein de MAYOLY et permet au Groupe de poursuivre son déploiement à l’international dans des pays à fort potentiel. Ces récentes ouvertures portent à 23 le nombre de ses filiales à travers le monde.

La filiale en Tunisie, ouverte en juillet 2023, prend en charge la promotion d’un portefeuille unifié de solutions de santé, en gastroentérologie, à travers le pays.

Les filiales basées en Algérie, République Tchèque, Lituanie, Pologne, Roumanie et Slovaquie, ouvertes en janvier 2024, marquent une étape importante dans la poursuite de l’internationalisation de Mayoly. Ces nouvelles filiales ont également pour mission de promouvoir et commercialiser le portefeuille unifié de solutions de santé en gastroentérologie, en s’appuyant sur un solide réseau de distribution local.

Cette expansion représente une étape importante dans l’ambition de MAYOLY d’étendre sa présence mondiale et continuer à investir sur de nouveaux marchés.

Fort de son réseau mondial avec 23 filiales à travers le monde et plus de 2 200 collaborateurs, MAYOLY est à présent positionné, pour continuer son développement afin d’apporter des bénéfices concrets aux patients et aux consommateurs avec des solutions de santé et de bien-être efficaces, fiables et accessibles au plus grand nombre, à travers le monde.

Mayoly Spindler announces that it has entered exclusive negotiations with IPSEN (IPN) to acquire its Consumer Healthcare branch, which includes established brands such as Smecta®, Forlax® and Tanakan®, recognized by practitioners and patients worldwide, and distributed in more than 80 countries.

This acquisition would be in line with Mayoly Spindler’s development strategy. A French, family-owned and independent pharmaceutical group, Mayoly Spindler seeks to become one of the world’s leading gastroenterology and dermocosmetics companies through this acquisition. The company has built its development around specialties that are also recognized worldwide, such as Meteospasmyl®, Probiolog® or Topicrem®, many of which are complementary to Ipsen CHC’s therapeutic solutions.

This transaction would accelerate Mayoly Spindler’s development and strengthen its long-term ambition of being a top ten European OTC drugs players as well as becoming part of the top 5 European OTC gastroenterology drugs provider over the next 10 years. With 2,200 employees across all continents, the new entity would benefit from a strong industrial footprint in France, portfolio complementarities in its therapeutic areas, unique commercial synergies and pooled investments in research and development.

“We are proud to be retained by Ipsen as the acquiror of their CHC business, and we look forward to welcoming their employees in order to build together a leading player in consumer healthcare, relying on world-renowned pharmaceutical specialties, a strong industrial footprint in France and a global presence,” said Jean-Nicolas Vernin, Chairman, and Nicolas Giraud, CEO of Mayoly Spindler.

In addition to the support of the historical banking partners, Capza and Caravelle, two French and European financial partners specialized in operations of this scale, will supply part of the funds required to complete this transaction, by acquiring a minority stake in the combined entity.

“We are particularly pleased to support this ambitious growth project in an industry we know well, and to contribute to the creation of a French champion in consumer healthcare”, commented Lorène Martel, President of Caravelle, Guillaume Basquin and Frédéric Chiche, Partners and Co-Heads of Capza Expansion.

The proposed acquisition will be subject to the consultation of employee representative bodies, as well as the finalization of the legal documentation and the customary authorizations, in accordance with the regulations in force. Mayoly Spindler expects to complete the acquisition in the third quarter of 2022.

***

Media Contacts
Florian Ridard / %66%6C%6F%72%69%61%6E%2E%72%69%64%61%72%64%40%76%61%65%2D%73%6F%6C%69%73%2E%63%6F%6D / +33 7 69 59 14 95
Alexis de Maigret / %61%6C%65%78%69%73%2E%64%65%6D%61%69%67%72%65%74%40%76%61%65%2D%73%6F%6C%69%73%2E%63%6F%6D / + 33 6 13 62 38 23

***

About Mayoly Spindler
Founded in 1909, Mayoly Spindler is a French, international and independent pharmaceutical company, specialising in Gastroenterology and Dermo-cosmetics. With over 50% of its turnover generated internationally, Mayoly Spindler is continuing its development which started over 110 years ago. With their own production facilities, Mayoly Spindler is able to manage its own industrial developments. Therefore, 62% of the products it sells are made in France. Mayoly Spindler values entrepreneurship, pragmatism and accountability within a caring organisation. All Mayoly Spindler teams work together to build the future of the company and contribute to its global ambitions. Mayoly Spindler is a health entrepreneur committed to supporting patients every day in their well-being and health. To learn more, please visit: https://mayoly.com/en/ or follow us on Twitter and LinkedIn.

About Ipsen CHC
Ipsen’s purpose in consumer healthcare is to bring people across the world care and comfort in their daily lives with healthcare solutions they can trust. Ipsen Consumer HealthCare develops and markets a wide range of innovative solutions – drugs, medical devices and probiotics – in four therapeutic areas: gastroenterology, cognitive disorders, pain, cough and cold. Ipsen Consumer HealthCare is present in 80 countries and employs 1,200 people.

During 4 days, International & Business Team managed our booth at Arab Health, the largest gathering of healthcare/Pharma in the MEA region. The 2018 edition included more than 4,200 exhibiting companies and more than 10,000 attendees from 150+ countries (mainly from MEA region). Our partner in Emirates & Saudi Arabia, Gulf Drug, was gold sponsor of the event, and we received very good feedback of their expertise in the Region.

Mayoly booth was based on French Pavillon even if our neighbour were from Belgium ! Was highlighted the Topicrem products, the HP Franchise with 1 KIBION DYNAMIC & 1 HELIPROBE, the IBS family and the Probiotics franchise, in addition to all others products of the Mayoly.

Supporting for a part the Contract Manufacturing activities (and Calcidose received  a very good feedback !), the main objective was to (1) to find new products, and (2) to find new partners for new countries.

After around 200 business cards exchanges, and 4 exhausting days, the conclusion is very positive. We met a lot of Pharmaceutical companies & distributors from Emirates, Saudi Arabia, Iran, Irak, Syria, Jordan, Kuwait, Oman, Bahrain, Yemen, for Middle East, or Kenya and Sudan for Africa for example.

Products presentation, company introduction have been done already, and the follow-up of this event is now crucial, to be able to valuate these 4 days, by new business openings. Our key products have been plebiscited, but some others products, not targeted as priority, may have some potential based on the number of interests received (Colchicine, Calcidose, Cholurso, and the suppository range).

We hope now that business cases arriving in the coming months will be approved to increase our business level in this part of the world, where market growth is very interesting.

We already took an appointment for next year!